Squarepoint Ops LLC Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Squarepoint Ops LLC raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 155.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,176 shares of the company's stock after acquiring an additional 25,034 shares during the period. Squarepoint Ops LLC owned 0.08% of Janux Therapeutics worth $2,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in JANX. Barclays PLC grew its position in shares of Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after acquiring an additional 144,883 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after purchasing an additional 1,095 shares during the period. Chicago Capital LLC acquired a new stake in Janux Therapeutics during the 4th quarter worth $230,000. abrdn plc purchased a new position in Janux Therapeutics during the 4th quarter worth $3,430,000. Finally, Lester Murray Antman dba SimplyRich grew its position in Janux Therapeutics by 205.3% during the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after purchasing an additional 16,351 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on JANX shares. HC Wainwright reiterated a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Wedbush reaffirmed an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, Scotiabank lowered their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $95.25.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now directly owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. The trade was a 3.67% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at approximately $2,640,768.85. This represents a 3.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,001 shares of company stock worth $313,964. 8.10% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Performance

JANX traded down $0.33 during trading on Friday, reaching $23.71. The company's stock had a trading volume of 1,055,845 shares, compared to its average volume of 884,427. The company's fifty day moving average price is $27.37 and its 200-day moving average price is $38.67. Janux Therapeutics, Inc. has a 52-week low of $22.48 and a 52-week high of $71.71. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -20.26 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.